NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data

NGM Biopharmaceuticals (NASDAQ: NGM) revealed preliminary data on Monday showing that 22 percent of patients who received its experimental NASH drug, aldafermin, as part of the last of four cohorts enrolled in its Phase 2 study of the drug met a composite goal of an improvement in liver fibrosis, or scarring, and resolution of NASH after 24 weeks of treatment. Zero percent of patients who received a placebo met the goal.